Familial Adenomatous Polyposis (FAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Familial Adenomatous Polyposis (FAP) Market Outlook

Thelansis’s “Familial Adenomatous Polyposis (FAP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Adenomatous Polyposis (FAP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Familial Adenomatous Polyposis (FAP) Overview

Familial adenomatous polyposis (FAP) is an inherited condition that primarily affects the gastrointestinal tract. This condition causes hundreds or thousands of polyps to form inside the colon and rectum. This condition is also known as hereditary polyposis of the colorectum, Gardner's syndrome, and familial polyposis. Nearly 100% progression to colorectal cancer (CRC) by the age of 35–40 yr and a heightened risk of various other malignancies. Familial adenomatous polyposis (FAP) is a highly penetrant autosomal-dominant disorder caused by a germline mutation in the adenomatous polyposis coli (APC) gene, located on chromosome 5q21. Over 700 different disease-causing APC mutations have been reported to date. However, the most common germline mutation involves the introduction of a premature stop codon, either by a nonsense mutation (30%), frameshift mutation (68%), or large deletion (2%), leading to truncation of the protein product in the C-terminal region.

• The birth frequency of Familial adenomatous polyposis (FAP) in the USA and European populations is estimated at roughly 1.5 in 15,000 to 1.89 in 18,000 live births, respectively. It is also responsible for less than 1% of all CRC cases.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: